Develop Your Biobank by Optimising Sample Quality & Making Robust Use of Your Samples
By 2020, almost 70% of all drugs will be biological compounds.
With the key focus now on using your biobank as effectively as possible, commercial biobanks becoming a common theme and data analytics being carried out on samples, the face of biobanking is evolving.
Instead of storing multiple samples and trying to find a use for them, working backwards has been key to the developments in this field. Working out what samples are needed in research and then seeking these specifically is the way to be sustainable.
With this in mind, Pharma IQ presents the 13th Annual Global Biobanking Summit.
The draft agenda is under construction and will be available for download in the next few weeks so please keep checking back! Alternatively, if you are interested in a pass to the event, please enquire here.
Key Sessions from the 2015 event included:
- Explore the latest initiatives to harmonise sample quality and data standards with Anne Carter, UCL, and Georges Dagher, INSERM
- Develop best practice to obtain samples globally and track consent with Karina Bienfait, Merck
- Evaluate effective processses to ensure sample quality and integrity with Victoria Haggerson, GSK, and Cheryl Gillett, KCL
- Increase sample utilisation and create a collaborative public-private partnership with Francisco de Luna, CNIO, and John Spaull, GSK
“Excellent content - very valuable” National Cancer Institute
“Very nice presentations withspot on subjects. Very good sessions” Erasmus MC Tissue Bank
“In such a topically diverse area, IQPC delivered a top class agenda with speakers and delegates to match” Qiagen